Costo-Efficacia di cabozantinib nel trattamento di seconda linea del tumore a cellule renali metastatico (mRCC) in Italia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Costo-Efficacia di cabozantinib nel trattamento di seconda linea del tumore a cellule renali metastatico (mRCC) in Italia

Published:2018-01 Issue: Volume:2018 Page:228424031879073
ISSN:2284-2403
Container-title:Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish
language:en
Short-container-title:Global & Regional Health Technology Assessment

Author:

Stanisic Sanja¹,Cicchetti Americo²,Porta Camillo³,Procopio Giuseppe⁴,Berto Patrizia¹

Affiliation:

1. Analytica LASER, a Certara company, Milano, Italia

2. Facoltà di Economia dell’Università Cattolica del Sacro Cuore, Roma, Italia

3. Università degli Studi di Pavia e IRCCS Policlinico San Matteo di Pavia, Pavia, Italia

4. Oncologia medica genitourinaria, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italia

Publisher

Aboutscience Srl

Subject

Health Policy

Link

http://journals.sagepub.com/doi/pdf/10.1177/2284240318790734

Reference19 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review

3. Epidemiology and outcome of sarcomatoid renal cell cancer compared to clear cell renal cancer: A Surveillance, Epidemiology, and End Results (SEER) database review.

4. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study

5. Pharmacotherapy for treating metastatic clear cell renal cell carcinoma

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP